Premium
Molecular testing for lung adenocarcinoma: Is it time to adopt a “plasma‐first” approach?
Author(s) -
Makarem Maisam,
Leighl Natasha B.
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32875
Subject(s) - medicine , lung , oncology , adenocarcinoma , precision medicine , lung cancer , intensive care medicine , pathology , bioinformatics , cancer research , cancer , biology
There is growing evidence that plasma cell‐free DNA testing can aid in the diagnosis of targetable alterations at diagnosis in patients with advanced nonsquamous lung carcinoma. A plasma‐first approach will facilitate access to precision medicine, with studies suggesting that nearly 60% of patients could benefit compared with the current approach of tissue profiling alone.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom